<DOC>
	<DOCNO>NCT02482428</DOCNO>
	<brief_summary>The LFX453X2202 study test investigational drug LFX453 placebo safety , tolerability , efficacy treat genital wart circumcise men , parallel additional open label arm use imiquimod 5 % . During study patient receive either LFX453 , placebo active comparator tolerability safety assess continuously local tolerability assessment adverse event record . Efficacy clinical evaluation lesion count . During study biopsy take analysis pharmacokinetics biomarkers . Blood sample take safety , pharmacokinetics ( PK ) , biomarkers .</brief_summary>
	<brief_title>Efficacy Tolerability Topical LFX453 External Genital Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Signed informed consent Circumcised male 1860 year Clinical diagnosis external genital wart Agree remain abstinent use condom intercourse duration study Agree digital photograph treat area Any treatment genital wart within one month treatment start HPV vaccination presence wart large 200 mm2 Genital herpes within one month treatment start History Bowenoid papulosis significant illness within 2 week treatment start use investigational drug know hypersensitivity study drug constituent history ECG abnormalities History significant heart condition Impaired renal function Abnormal liver function History immunodeficiency disease Drug alcohol abuse Immunosuppressive therapy Malignancies past 5 year hypertrophic scarring</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>human papilloma virus ( HPV ) , Genital Warts , Sexually transmit disease ( STD ) , viral disease</keyword>
</DOC>